Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
– Received U.S. Food and Drug Administration (FDA) approval of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity […]
Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress
– Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant […]
LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
Focused on the evaluation of strategic alternatives Adopted a restructuring plan to extend capital resources, incurring a reduction in workforce […]
Atlantic International Corp. Reports Strong 2024 Results with Over $442 Million in Revenue; Over 10% Revenue Growth
Company Completes First Quarter Publicly-Traded on Nasdaq Global Market under “ATLN” Announces Strategic Developments and Outlook; Targets $1 to $1.5 […]
Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851
THE WOODLANDS, Texas, March 28, 2025 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has entered […]
Flow Capital Announces $1.5 Million of Follow-On Investments to a Fintech Company
TORONTO, March 28, 2025 (GLOBE NEWSWIRE) — Flow Capital Corp. (TSXV:FW) (“Flow Capital” or the “Company”), a leading provider of […]
Prospect Capital’s Credit Ratings Reaffirmed Investment Grade by Morningstar DBRS with Stable Trend
NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) — Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”, “our”, or “we”) today announced that […]
Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS
RIPSA interests repurchased Term loan facility increased to $450 million with more favorable terms Access to up to an additional […]
CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates
– Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) – [...]
Bio-Path Holdings Reports Full Year 2024 Financial Results
HOUSTON, March 28, 2025 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi […]
